The tumor molecular signature has a strong prognostic value in high-risk EC POLE-mutated patients’ better outcomes versus a worse outcome for p53 abnormal patients, with the MSI and NSMP groups having an intermediate outcome [35]. This evidence concerns the gene POLE and neoplasm.